Updated 22 August 2012 (originally posted December 2011)
At Cell Therapy Group, we track cell therapy industry activity globally but particularly activity related to the clinical development and commercialization of cell based therapeutic products globally.
Below is a synopsis of the pivotal, phase 3 or 2/3 industry-sponsored cell therapy trials we are currently tracking globally.
There is a database behind this that includes more data fields like therapeutic category, cell/tissue source, cell type, expansion, indication, expected completion date, clinical trial site locations, etc.
At Cell Therapy Group, we track cell therapy industry activity globally but particularly activity related to the clinical development and commercialization of cell based therapeutic products globally.
Below is a synopsis of the pivotal, phase 3 or 2/3 industry-sponsored cell therapy trials we are currently tracking globally.
There is a database behind this that includes more data fields like therapeutic category, cell/tissue source, cell type, expansion, indication, expected completion date, clinical trial site locations, etc.
*active or expected to be active in 2012
Aastrom
- Ixmyelocel-T
- Arcelis - AGS-003
- ReCell
- ACT34-CMI
Bone Therapeutics
- PROEB
- C-CURE
Cell Medica
- adoptive cellular therapy
- INSTRUCT
- CAOMECS (Cultured Autologous Oral Mucosal Epithelial Cell-Sheet)
- co.don chondrosphere
- AMDC
Cytori
- ADRCs
- CAIS
- GRASPA
GamidaCell - Teva
- StemEx
- SmartPReP 2 BMAC
Healthpoint
- HP802-247
- NeoCart
- Immunecell-LC
- IES13 (Urocell?)
ISTO Technologies
- DeNovo ET
- CreaVax-RCC
Kiaidis Pharma
- ATIR
- CureXcell
- Revascor
- CliniMACS CD34 Selection System
MolMed
- TK
Newlink Genetics
- HyperAcute Pancreas
NKBio
- Biocell Natural Killer Mixture
- DCVax-L
- Lucanix
NuVasive
- Osteocel Plus
- Prochymal
- Heartcellgram-AMI
Prima Biomed
- Cvac
- MACI
- DVAC/Pca
- Cx601
- CAIS
- amniotic membrane
Some of the products listed above are in more than one clinical trial - different regions and/or different indications.
In total we are tracking 48 industry sponsored, active (or expected to be active 2012) cell therapy trials in pivotal, ph III or II/III expected to involve over 11,000 patients. Some of the products listed above are the subject of multiple trials.
The 50 trials are sponsored by 40 companies. The trials roughly break down as follows:
- 59% are autologous
- 45% are allogeneic
- Two are gene-modified allogeneic
- One involves autologous and allogeneic cells (we counted it for both)
- 30% for oncology or related indications
- 13% for cardiac-related indications
- 13% for non-cardiovascular (PAD, CLI, VLU, etc) & wound
- 34% (6) for cartilage and bone repair
___________________________________
I encourage readers to comment below or email direct with any errors and/or omissions.
2 comments:
Thanks to ISTO Technologies for reminding me to include their phase III trial of DeNovo ET for articular cartilage defects. DeNovo ET is a neocartilage implant surgically implanted and affixed to subchondral bone using commercial fibrin during mini-open knee arthrotomy. The Neocartilage Implant is a cartilage repair technology cultured from allogeneic juvenile human cartilage cells.
You always add value. Thanks.
Post a Comment